Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes revenue by revenue source as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
Major Products/Service Lines (in thousands)	2022		2021		2022		2021
Product revenue, net(1)	$	233,366	$	96,678	$	631,157	$	277,559
License and royalty revenues(2)	5,926		5,395		40,738		18,087
Total revenues	$	239,292	$	102,073	$	671,895	$	295,646

________________________________

(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are primarily categorized within product revenue, net. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

Revenue by product category on a net basis is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
DEFINITY	$	60,740	$	57,636	$	181,374	$	173,448
TechneLite	22,094		22,680		64,139		69,252
Other precision diagnostics	6,175		7,563		16,803		21,289
Total precision diagnostics	89,009		87,879		262,316		263,989
PYLARIFY	143,754		7,724		366,763		7,997
Other radiopharmaceutical oncology	928		1,166		3,183		5,206
Total radiopharmaceutical oncology	144,682		8,890		369,946		13,203
Strategic partnerships and other revenue	5,601		5,304		39,633		18,454
Total revenues	$	239,292	$	102,073	$	671,895	$	295,646